Amgen Gets The First BiTE
Executive Summary
On December 3, FDA approved Amgen Inc.’s bispecific T-cell engager (BiTE) Blincyto for forms of relapsed or refractory acute lymphocytic leukemia, less than two months after accepting the company’s Biologics License Application and more than five months ahead of its user-fee goal of May 19, 2015.
You may also be interested in...
Immunotherapy: Big Pharma’s Seductive Embrace
The oncology community believes that immunotherapy will be foundational, in the same way that combination chemotherapy became the backbone of treatment in the 1970s. The marching order is to trial broadly, quickly, making clinical development particularly well-suited for Big Pharma.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.